Partnering with Linio Biotech
A large, growing market undergoing a structural shift
market
Linio Biotech is targeting the $23.8B global aesthetic injectables market, which continues to grow at approximately 11% CAGR. This growth is not only driven by increasing demand, but by a fundamental shift in how aesthetic outcomes are defined and delivered.
The market is moving away from synthetic, volume-heavy approaches toward solutions that emphasize natural appearance, subtle correction, and biological integration.
From filling to bio stimulation and regeneration
Patient and physician preferences are evolving rapidly:
- Excessive filling is being replaced by biostimulatory and regenerative outcomes
- Desired results are subtle, natural enhancements, not immediately obvious cosmetic changes
- Natural movement and tissue behavior are increasingly valued — something synthetic fillers struggle to achieve
- Longevity and tissue health are becoming as important as immediate visual correction
These trends strongly favor technologies that support the body’s own regenerative processes, rather than simply occupying space.
Fastest-growing segment: regenerative injectables
While synthetic hyaluronic acid fillers still dominate today, regenerative and biologically active solutions are gaining rapid traction.
This segment is projected to grow at approximately ~20% annually, significantly outpacing the overall market. Linio Biotech is deliberately positioned to address this fastest-growing, highest-value segment, where differentiation, innovation, and clinical credibility matter most.
Our upcoming product directly aligns with these trends by combining:
- Immediate aesthetic correction
- Biological support for long-term tissue formation
- Natural, durable outcomes
FOR INVESTORS
Linio Biotech offers a rare combination of attributes that are sought after by strategic investors and partners:
- Clinically validated foundation
Tience® is already used in routine clinical practice, generating real-world data and physician engagement. - Platform potential beyond a single product
One core technology enabling multiple regenerative indications and pipeline expansion. - Strong regulatory and operational backbone
In-house licensed tissue establishment providing end-to-end control, scalability, and compliance. - Clear value inflection points ahead
Progression toward MDR and FDA pathways, expanding clinical data, and next-generation product development. - Strategic relevance in an M&A-driven market
Designed to integrate into the portfolios of global medical aesthetics and dermatology leaders.
Investment focus
We engage with investors who share our long-term vision of advancing regenerative aesthetics and understand the value of early positioning in platform technologies.
We are particularly aligned with:
- Strategic investors in medical aesthetics and dermatology
- Healthcare-focused venture and growth investors
- Corporate venture arms and innovation units
- Partners seeking early access to regenerative platforms
Built for partnership and strategic outcomes
Linio Biotech is intentionally structured to support strategic collaboration, including licensing, co-development, and acquisition opportunities.
Our goal is to create a company and technology platform that:
- Reduces risk through early clinical validation
- Accelerates partner pipelines
- Expands access to regenerative solutions globally
Linio news highlights
Here you can read more about our latest updates
Funding and traction
Linio Biotech has raised over €10 million to date through equity investments and public grants. The company operates with a lean structure and strong cost control to maximize capital efficiency.
investments, inquiries & Partnerships
Interested in putting your skin in the game?